Phase II pilot study of FOLFOXIRI plus panitumumab in metastatic RAS wild-type left-sided colorectal cancer

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions:
    Metastatic Ras Wild-type, Left Sided Colorectal Cancer
  • Age: Between 18 - 100 Years
  • Gender: Male or Female
  • Other Inclusion Criteria:
    1) Histologically confirmed diagnosis of advanced adenocarcinoma of the colon or rectum (colorectal cancer). 2) No previous systemic chemotherapy for metastatic disease -Subjects who have had prior adjuvant chemotherapy for non-metastatic disease are eligible if more than six months have elapsed after completing therapy. 3) RAS wild-type; left-sided tumor 4) ECOG performance status of 0-1.

You may not be eligible for this study if the following are true:

  • 1) Subjects with > grade 1 neuropathy. 2) Any active or uncontrolled infection. 3) Clinically significant cardiovascular disease within the past 6 months. 4) Major surgical procedure within 28 days prior to the start of study treatment.


If you are registered as a volunteer, please login to the dashboard to send referrals.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.